The effects of risperidone titration on pica in an adolescent with autism

Andrew W Gardner, Rebecca Ernst, Julia T. O'Connor, Peter T. Daniolos, Varsha Morar, Lindsay P. Richerson

Research output: Contribution to journalArticle

Abstract

Pica, or the ingestion of inedible objects, is a common problem in people diagnosed with disabilities. Pica can lead to a variety of health complications including surgical interventions. However, inconsistencies in prevalence data are acknowledged due to the unreliable definitions of pica and the lack of data reported on non-residential individuals.24 Some studies have reported that pharmaceuticals, such as risperidone, can have adverse effects on children with disabilities. The present study provides an overview of the literature reporting the use of risperidone with children diagnosed with Autism and other Pervasive Developmental Disorders, as well as an example of possible counter therapeutic effects of risperidone on the appropriate and inappropriate behavior of a 13-year-old Hispanic female diagnosed with Autism. Measurement of behaviors included direct (i.e. direct observation) and indirect (Conners' Rating Form - Revised) methods. Risperidone had been originally prescribed for hyperactive and aggressive behaviors and dosages were titrated down from .50 mg to no medication over six weeks while data were collected on pica, aggression, and appropriate play behaviors in the home setting. Reliability data were collected for 75% of all sessions with an average of 81% agreement across observers. Results are discussed in relation to adverse effects and the cost/benefit of using risperidone with children diagnosed with Autism and Pervasive Developmental Disorders.

Original languageEnglish (US)
Pages (from-to)144-150
Number of pages7
JournalInternational Pediatrics
Volume23
Issue number3
StatePublished - Sep 2008

Fingerprint

Pica
Risperidone
Autistic Disorder
Disabled Children
Therapeutic Uses
Disabled Persons
Aggression
Hispanic Americans
Cost-Benefit Analysis
Eating
Observation
Health
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Gardner, A. W., Ernst, R., O'Connor, J. T., Daniolos, P. T., Morar, V., & Richerson, L. P. (2008). The effects of risperidone titration on pica in an adolescent with autism. International Pediatrics, 23(3), 144-150.

The effects of risperidone titration on pica in an adolescent with autism. / Gardner, Andrew W; Ernst, Rebecca; O'Connor, Julia T.; Daniolos, Peter T.; Morar, Varsha; Richerson, Lindsay P.

In: International Pediatrics, Vol. 23, No. 3, 09.2008, p. 144-150.

Research output: Contribution to journalArticle

Gardner, AW, Ernst, R, O'Connor, JT, Daniolos, PT, Morar, V & Richerson, LP 2008, 'The effects of risperidone titration on pica in an adolescent with autism', International Pediatrics, vol. 23, no. 3, pp. 144-150.
Gardner AW, Ernst R, O'Connor JT, Daniolos PT, Morar V, Richerson LP. The effects of risperidone titration on pica in an adolescent with autism. International Pediatrics. 2008 Sep;23(3):144-150.
Gardner, Andrew W ; Ernst, Rebecca ; O'Connor, Julia T. ; Daniolos, Peter T. ; Morar, Varsha ; Richerson, Lindsay P. / The effects of risperidone titration on pica in an adolescent with autism. In: International Pediatrics. 2008 ; Vol. 23, No. 3. pp. 144-150.
@article{e4db7fe6e69b4baeabf26d7bb99e5f94,
title = "The effects of risperidone titration on pica in an adolescent with autism",
abstract = "Pica, or the ingestion of inedible objects, is a common problem in people diagnosed with disabilities. Pica can lead to a variety of health complications including surgical interventions. However, inconsistencies in prevalence data are acknowledged due to the unreliable definitions of pica and the lack of data reported on non-residential individuals.24 Some studies have reported that pharmaceuticals, such as risperidone, can have adverse effects on children with disabilities. The present study provides an overview of the literature reporting the use of risperidone with children diagnosed with Autism and other Pervasive Developmental Disorders, as well as an example of possible counter therapeutic effects of risperidone on the appropriate and inappropriate behavior of a 13-year-old Hispanic female diagnosed with Autism. Measurement of behaviors included direct (i.e. direct observation) and indirect (Conners' Rating Form - Revised) methods. Risperidone had been originally prescribed for hyperactive and aggressive behaviors and dosages were titrated down from .50 mg to no medication over six weeks while data were collected on pica, aggression, and appropriate play behaviors in the home setting. Reliability data were collected for 75{\%} of all sessions with an average of 81{\%} agreement across observers. Results are discussed in relation to adverse effects and the cost/benefit of using risperidone with children diagnosed with Autism and Pervasive Developmental Disorders.",
author = "Gardner, {Andrew W} and Rebecca Ernst and O'Connor, {Julia T.} and Daniolos, {Peter T.} and Varsha Morar and Richerson, {Lindsay P.}",
year = "2008",
month = "9",
language = "English (US)",
volume = "23",
pages = "144--150",
journal = "International Pediatrics",
issn = "0885-6265",
publisher = "Miami Children's Hospital Medical Journal Inc.",
number = "3",

}

TY - JOUR

T1 - The effects of risperidone titration on pica in an adolescent with autism

AU - Gardner, Andrew W

AU - Ernst, Rebecca

AU - O'Connor, Julia T.

AU - Daniolos, Peter T.

AU - Morar, Varsha

AU - Richerson, Lindsay P.

PY - 2008/9

Y1 - 2008/9

N2 - Pica, or the ingestion of inedible objects, is a common problem in people diagnosed with disabilities. Pica can lead to a variety of health complications including surgical interventions. However, inconsistencies in prevalence data are acknowledged due to the unreliable definitions of pica and the lack of data reported on non-residential individuals.24 Some studies have reported that pharmaceuticals, such as risperidone, can have adverse effects on children with disabilities. The present study provides an overview of the literature reporting the use of risperidone with children diagnosed with Autism and other Pervasive Developmental Disorders, as well as an example of possible counter therapeutic effects of risperidone on the appropriate and inappropriate behavior of a 13-year-old Hispanic female diagnosed with Autism. Measurement of behaviors included direct (i.e. direct observation) and indirect (Conners' Rating Form - Revised) methods. Risperidone had been originally prescribed for hyperactive and aggressive behaviors and dosages were titrated down from .50 mg to no medication over six weeks while data were collected on pica, aggression, and appropriate play behaviors in the home setting. Reliability data were collected for 75% of all sessions with an average of 81% agreement across observers. Results are discussed in relation to adverse effects and the cost/benefit of using risperidone with children diagnosed with Autism and Pervasive Developmental Disorders.

AB - Pica, or the ingestion of inedible objects, is a common problem in people diagnosed with disabilities. Pica can lead to a variety of health complications including surgical interventions. However, inconsistencies in prevalence data are acknowledged due to the unreliable definitions of pica and the lack of data reported on non-residential individuals.24 Some studies have reported that pharmaceuticals, such as risperidone, can have adverse effects on children with disabilities. The present study provides an overview of the literature reporting the use of risperidone with children diagnosed with Autism and other Pervasive Developmental Disorders, as well as an example of possible counter therapeutic effects of risperidone on the appropriate and inappropriate behavior of a 13-year-old Hispanic female diagnosed with Autism. Measurement of behaviors included direct (i.e. direct observation) and indirect (Conners' Rating Form - Revised) methods. Risperidone had been originally prescribed for hyperactive and aggressive behaviors and dosages were titrated down from .50 mg to no medication over six weeks while data were collected on pica, aggression, and appropriate play behaviors in the home setting. Reliability data were collected for 75% of all sessions with an average of 81% agreement across observers. Results are discussed in relation to adverse effects and the cost/benefit of using risperidone with children diagnosed with Autism and Pervasive Developmental Disorders.

UR - http://www.scopus.com/inward/record.url?scp=52249090635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52249090635&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:52249090635

VL - 23

SP - 144

EP - 150

JO - International Pediatrics

JF - International Pediatrics

SN - 0885-6265

IS - 3

ER -